Clinical Pharmacology and Therapeutics
A Textbook of Clinical Pharmacology and ... - clinicalevidence
A Textbook of Clinical Pharmacology and ... - clinicalevidence
- No tags were found...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
LIVER DISEASE 261<br />
withdrawal), small doses of benzodiazepines that are<br />
metabolized to inactive glucuronide conjugates, e.g.<br />
oxazepam are preferred to those with longer-lived<br />
metabolites. The hazards of narcotic analgesics to the<br />
patient with acute or chronic liver disease cannot be overemphasized;<br />
• prophylactic broad-spectrum intravenous antibiotics,<br />
especially if there is evidence of infection (e.g.<br />
spontaneous peritonitis);<br />
• intravenous acetylcysteine (the precise value of this has<br />
not yet been fully confirmed).<br />
Key points<br />
Treatment of hepatic encephalopathy<br />
• Supportive.<br />
• Measures to reduce absorption of ammonia from the<br />
gut (e.g. low-protein diet, lactulose neomycin).<br />
• Prophylactic broad spectrum antibiotics, prompt<br />
treatment of infection.<br />
• Prophylactic vitamin K.<br />
• Fresh frozen plasma/platelets as indicated.<br />
• H 2 antagonist (e.g. ranitidine) or proton-pump inhibitor<br />
(e.g. omeprazole) to prevent gastric erosions <strong>and</strong><br />
bleeding.<br />
• i.v. acetylcysteine (unproven).<br />
• Avoidance of sedatives, potassium-losing diuretics,<br />
opioids, drugs that cause constipation <strong>and</strong> hepatotoxic<br />
drugs whenever possible.<br />
DRUG THERAPY OF PORTAL HYPERTENSION AND<br />
OESOPHAGEAL VARICES<br />
Oesophageal varices form a collateral circulation in response to<br />
raised blood pressure in the portal system <strong>and</strong> are of clinical<br />
importance because of their tendency to bleed. Two-thirds of<br />
patients with varices die as a result <strong>and</strong> of these, one-third die<br />
of the first bleed, one-third rebleed within six weeks <strong>and</strong> only<br />
one-third survive for one year. Sclerotherapy <strong>and</strong> surgical shunt<br />
procedures are the mainstay of treatment, <strong>and</strong> drug therapy<br />
must be judged against these gloomy survival figures. In addition<br />
to resuscitation, volume replacement <strong>and</strong>, when necessary,<br />
balloon tamponade using a Sengstaken–Blakemore tube, the<br />
emergency treatment of bleeding varices may include vasoconstrictor<br />
drugs, e.g vasopressin analogues. These reduce portal<br />
blood flow through splanchnic arterial constriction.<br />
Drugs currently used for the management of acute variceal<br />
haemorrhage include octreotide (the long-acting analogue of<br />
somatostatin), vasopressin <strong>and</strong> terlipressin (a derivative of<br />
vasopressin). Terlipressin <strong>and</strong> octreotide are used to reduce<br />
portal pressure urgently, to control bleeding before more definitive<br />
treatment, such as sclerotherapy or variceal b<strong>and</strong>ing. Betablockers<br />
<strong>and</strong> vasodilators, such as nitrates, are used for<br />
long-term therapy to reduce portal pressure. Somatostatin <strong>and</strong><br />
its long-acting analogue octreotide reduce blood flow <strong>and</strong> cause<br />
a significant reduction in variceal pressure without effects on the<br />
systemic vasculature. To date, a clear-cut response in variceal<br />
bleeding has not been demonstrated. Side effects include vomiting,<br />
anorexia, abdominal pain, diarrhoea, headache <strong>and</strong> dizziness.<br />
Newer vasoactive drugs, such as terlipressin, appear to<br />
have a better therapeutic index <strong>and</strong> fewer side effects, although<br />
terlipressin has a short half-life <strong>and</strong> needs to be administered<br />
frequently or as an infusion.<br />
A number of trials have demonstrated efficacy of noncardioselective<br />
beta-adrenergic antagonists (propranolol,<br />
nadolol) in reducing the incidence of gastro-intestinal bleeding<br />
in patients with portal hypertension, especially in combination<br />
with endoscopic sclerotherapy.<br />
MANAGEMENT OF CHRONIC VIRAL HEPATITIS<br />
Chronic viral hepatitis is associated with chronic liver disease,<br />
cirrhosis <strong>and</strong> hepatocellular carcinoma. The carrier rate for<br />
hepatitis B in the UK is 0.1–1% (it is particularly prevalent in<br />
socially deprived areas of inner cities) <strong>and</strong> the seroprevalence<br />
for hepatitis C is 0.1–0.7%. Chronic viral hepatitis is diagnosed<br />
when there is evidence of continuing hepatic damage <strong>and</strong><br />
infection for at least six months after initial viral infection. In<br />
hepatitis C, the liver function may remain normal for months<br />
to years, while the patient’s blood remains infectious (confirmed<br />
by hepatitis C virus RNA detection). The course of the<br />
liver damage often fluctuates. While up to 90% of patients<br />
with acute hepatitis B clear the virus spontaneously, up to 60%<br />
of those with hepatitis C virus do not do so. About 20% of<br />
those with chronic active hepatitis progress insidiously to cirrhosis,<br />
<strong>and</strong> about 2–3% go on to develop hepatocellular carcinoma.<br />
Hepatitis B virus is a DNA virus that is not directly cytopathic<br />
<strong>and</strong> hepatic damage occurs as a result of the host<br />
immune response. Hepatocytes infected with hepatitis B virus<br />
produce a variety of viral proteins, of which the ‘e’ antigen<br />
(HBeAg) is clinically the most important. HBeAg is a marker for<br />
continued viral replication <strong>and</strong> therefore for infectivity.<br />
Hepatitis C virus is a single-str<strong>and</strong>ed RNA virus. Controlled<br />
trials have shown that interferon-alfa, lamivudine (a nucleoside<br />
analogue inhibitor of viral DNA polymerase) <strong>and</strong> adefovir<br />
dipivoxil (a phosphorylated nucleotide analogue inhibitor of<br />
viral DNA polymerases) are beneficial in reducing the viral<br />
load in patients with chronic hepatitis B virus infection.<br />
Pegylated interferon alfa-2a (peginterferon alfa-2a) may be<br />
preferred to interferon alfa. Pegylation (polyethylene glycolconjugation)<br />
prolongs the interferon half-life in the blood,<br />
allowing subcutaneous once weekly dosing. The National<br />
Institute of Health <strong>and</strong> <strong>Clinical</strong> Excellence (NICE) has recommended<br />
adefovir as an option in chronic hepatitis B if interferon<br />
is unsuccessful, if relapse occurs following successful initial<br />
interferon treatment, or if interferon is poorly tolerated or contraindicated<br />
(see Chapters 45 <strong>and</strong> 46).<br />
In chronic hepatitis C, the combination of peginterferon<br />
alfa <strong>and</strong> ribavarin (see Chapter 45) is recommended. Details<br />
on the regimens can be found at www.nice.org.uk/TA075.